Fixed ratio combination of basal insulin and GLP-1 receptor agonist
Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated
IDEGLIRA_SC_TIT_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.20 (-1.46 to -0.94) | 0.81 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.39 (-0.86 to 0.14) | 0.69 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD -0.26 (-1.27 to 0.72) | 0.66 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 2.51 (0.41 to 5.38) | 0.08 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.98 (-0.09 to 2.00) | 0.28 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -2.01 (-6.59 to 2.86) | 0.63 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 1.17 (0.32 to 5.56) | 0.81 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 14.36 (3.11 to 37.96) | 0.90 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 1.76 (0.49 to 5.51) | 0.71 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.82 (0.08 to 8.71) | 0.37 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.74 (1.36 to 5.16) | 0.21 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.68 (-4.62 to -0.84) | 0.58 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 6.98 (0.64 to 13.34) | 0.14 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.39 (-12.42 to 12.34) | 0.47 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.76 (-1.78 to 2.87) | 0.48 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.88 (0.65 to 1.18) | 0.56 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.62 (0.15 to 2.95) | 0.74 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.20 (0.79 to 1.87) | 0.75 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.41 (0.53 to 3.74) | 0.67 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.22 (0.85 to 1.79) | 0.63 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.17 (0.59 to 2.28) | 0.62 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.24 (0.02 to 2.19) | 0.74 |
Trials
- NCT05767255Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue2022 · 65 randomized · 4 weeks
- DUAL™ I ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)2017 · 720 randomized · 26 weeks
- DUAL™ II ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD2017 · 453 randomized · 26 weeks
- DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i2016 · 420 randomized · 26 weeks
- DUAL™ II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs2016 · 210 randomized · 26 weeks
- DUAL™ VIIIA Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus2016 · 1,012 randomized · 104 weeks
- NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus2015 · 506 randomized · 26 weeks
- DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 819 randomized · 52 weeks
- DUAL™ VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)2013 · 557 randomized · 26 weeks
- DUAL™IVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy2012 · 435 randomized · 26 weeks
- DUAL™ IIA 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes2011 · 413 randomized · 26 weeks